{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T04:10:26Z","timestamp":1744258226742,"version":"3.40.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00296-021-04800-y","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T16:05:57Z","timestamp":1613145957000},"page":"819-825","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Psoas abscess during treatment with intravenous tocilizumab in a patient with rheumatoid arthritis: a case-based review"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8977-6010","authenticated-orcid":false,"given":"Ines Doko","family":"Vajdi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2894-8069","authenticated-orcid":false,"given":"Goran","family":"\u0160timac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7083-7672","authenticated-orcid":false,"given":"Ivan","family":"Pezelj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1743-8709","authenticated-orcid":false,"given":"Matej","family":"Mustapi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3407-0317","authenticated-orcid":false,"given":"Simeon","family":"Grazio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,12]]},"reference":[{"key":"4800_CR1","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2165\/00003495-200969050-00007","volume":"69","author":"V Oldfield","year":"2009","unstructured":"Oldfield V, Dhillon S, Plosker GL (2009) Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs 69:609\u2013632. https:\/\/doi.org\/10.2165\/00003495-200969050-00007","journal-title":"Drugs"},{"key":"4800_CR2","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00296-017-3870-7","volume":"38","author":"L Baganz","year":"2018","unstructured":"Baganz L, Richter A, Kekow J, Bussmann A, Krause A, Stille C et al (2018) Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort. Rheumatol Int 38:579\u2013587. https:\/\/doi.org\/10.1007\/s00296-017-3870-7","journal-title":"Rheumatol Int"},{"key":"4800_CR3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, Burmester G, Dougados M, Kerschbaum A et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"key":"4800_CR4","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","volume":"381","author":"C Gabay","year":"2013","unstructured":"Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K et al (2013) Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet (London, England) 381:1541\u20131550. https:\/\/doi.org\/10.1016\/S0140-6736(13)60250-0","journal-title":"Lancet (London, England)"},{"key":"4800_CR5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ajem.2008.02.02711","volume":"27","author":"BR Taira","year":"2009","unstructured":"Taira BR, Singer AJ, Thode HC Jr, Lee CC (2009) National epidemiology of cutaneous abscesses: 1996 to 2005. Am J Emerg Med 27:289\u2013292. https:\/\/doi.org\/10.1016\/j.ajem.2008.02.02711","journal-title":"Am J Emerg Med"},{"key":"4800_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10096-011-1281-3","volume":"31","author":"VL Vaska","year":"2012","unstructured":"Vaska VL, Nimmo GR, Jones M, Grimwood K, Paterson DL (2012) Increases in Australian cutaneous abscess hospitalisations: 1999\u20132008. Eur J Clin Microbiol Infec Dis 31:93\u201396. https:\/\/doi.org\/10.1007\/s10096-011-1281-3","journal-title":"Eur J Clin Microbiol Infec Dis"},{"key":"4800_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1463-1318.2006.01135.x","volume":"9","author":"JP Garner","year":"2007","unstructured":"Garner JP, Meiring PD, Ravi K, Gupta R (2007) Psoas abscess\u2014not as rare as we think? Colorectal Dis 9:269\u2013274. https:\/\/doi.org\/10.1111\/j.1463-1318.2006.01135.x","journal-title":"Colorectal Dis"},{"key":"4800_CR8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/MD.0b013e31819d2748","volume":"88","author":"V Navarro L\u00f3pez","year":"2009","unstructured":"Navarro L\u00f3pez V, Ramos JM, Meseguer V, Arellano JLP, Serrano R, Ordonez MAG et al (2009) Microbiology and outcome of iliopsoas abscess in 124 patients. Medicine (Baltimore) 88:120\u2013130. https:\/\/doi.org\/10.1097\/MD.0b013e31819d2748","journal-title":"Medicine (Baltimore)"},{"key":"4800_CR9","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ijsu.2012.08.016","volume":"10","author":"D Shields","year":"2012","unstructured":"Shields D, Robinson P, Crowley TP (2012) Iliopsoas abscess\u2014a review and update on the literature. Int J Surg 10:466\u2013469. https:\/\/doi.org\/10.1016\/j.ijsu.2012.08.016","journal-title":"Int J Surg"},{"key":"4800_CR10","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409\u20131417. https:\/\/doi.org\/10.1007\/s00296-011-1999-3","journal-title":"Rheumatol Int"},{"key":"4800_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.idc.2020.02.003","volume":"34","author":"AY Liu","year":"2020","unstructured":"Liu AY (2020) Infectious implications of Interleukin-1, Interleukin-6, and T helper type 2 inhibition. Infect Dis Clin North Am 34:211\u2013234. https:\/\/doi.org\/10.1016\/j.idc.2020.02.003","journal-title":"Infect Dis Clin North Am"},{"key":"4800_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3899\/jrheum.130466","volume":"41","author":"T Koike","year":"2014","unstructured":"Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T et al (2014) Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol 41:15\u201323","journal-title":"J Rheumatol"},{"key":"4800_CR13","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s10165-010-0279-5","volume":"20","author":"N Nishimoto","year":"2010","unstructured":"Nishimoto N, Ito K, Takagi N (2010) Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 20:222\u2013232. https:\/\/doi.org\/10.1007\/s10165-010-0279-5","journal-title":"Mod Rheumatol"},{"key":"4800_CR14","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1093\/rheumatology\/key361","volume":"58","author":"P Emery","year":"2019","unstructured":"Emery P, Rondon J, Parrino J, Lin Y, Pena-Rossi C, van Hoogstraten H et al (2019) Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. Rheumatology (Oxford) 58:849\u2013858. https:\/\/doi.org\/10.1093\/rheumatology\/key361","journal-title":"Rheumatology (Oxford)"},{"key":"4800_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13075-015-0583-8","volume":"17","author":"R Sakai","year":"2015","unstructured":"Sakai R, Cho S-K, Nanki T, Watanabe K, Yamazaki H, Tanaka M et al (2015) Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. Arthritis Res Ther 17:74. https:\/\/doi.org\/10.1186\/s13075-015-0583-8","journal-title":"Arthritis Res Ther"},{"key":"4800_CR16","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.jos.2015.06.018","volume":"21","author":"T Tsujimoto","year":"2016","unstructured":"Tsujimoto T, Takahata M, Kokabu T, Matsuhashi M, Iwasaki N (2016) Pyogenic spondylodiscitis following anti-interleukin-6 therapy in a patient with rheumatoid arthritis (implication of hematogenous infection risk in degenerative intervertebral discs): a case report and review of the literature. J Orthop Sci 21:694\u2013697. https:\/\/doi.org\/10.1016\/j.jos.2015.06.018","journal-title":"J Orthop Sci"},{"key":"4800_CR17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41394-020-00341-x","volume":"6","author":"G Sampogna","year":"2020","unstructured":"Sampogna G, Tessitore N, Bianconi T, Leo A, Zarbo M, Montanari E (2020) Spinal cord dysfunction after COVID-19 infection. Spinal Cord Ser Cases 6:92. https:\/\/doi.org\/10.1038\/s41394-020-00341-x","journal-title":"Spinal Cord Ser Cases"},{"key":"4800_CR18","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1097\/IPC.0000000000000320","volume":"24","author":"E Douglass","year":"2016","unstructured":"Douglass E, Mondy K, Huth RG (2016) Salmonella epidural abscess in a patient with rheumatoid arthritis treated with tocilizumab. Infect Dis ClinPract 24:e7\u2013e8. https:\/\/doi.org\/10.1097\/IPC.0000000000000320","journal-title":"Infect Dis ClinPract"},{"key":"4800_CR19","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jiac.2019.02.005","volume":"25","author":"R Yamate","year":"2019","unstructured":"Yamate R, Matono T, Yaguchi T, Fujii Y, Goto Y, Tobino K et al (2019) Disseminated nocardiosis with Nocardia brasiliensis bacteremia in a patient with rheumatoid arthritis using tocilizumab. J Infect Chemother 25:552\u2013555. https:\/\/doi.org\/10.1016\/j.jiac.2019.02.005","journal-title":"J Infect Chemother"},{"key":"4800_CR20","first-page":"951","volume":"30","author":"MD de Kruif","year":"2012","unstructured":"de Kruif MD, van Gorp ECM, Bel EH, Gerlag DM, Kunst PW (2012) Streptococcal lung abscesses from a dental focus following tocilizumab: a case report. ClinExpRheumatol 30:951\u2013953","journal-title":"ClinExpRheumatol"},{"key":"4800_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2147\/TCRM.S155488","volume":"14","author":"S Zhou","year":"2018","unstructured":"Zhou S, Qiao J, Bai J, Wu Y, Fang H (2018) Biological therapy of traditional therapy-resistant adult-onset Still\u2019s disease: an evidence-based review. TherClin Risk Manag 14:167\u2013171. https:\/\/doi.org\/10.2147\/TCRM.S155488","journal-title":"TherClin Risk Manag"},{"key":"4800_CR22","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/rheumatology\/ker336","volume":"51","author":"MGH van de Sande","year":"2012","unstructured":"van de Sande MGH, van Slobbe-Bijlsma ER (2012) Necrotizing fasciitis in a rheumatoid arthritis patient treated with tocilizumab. Rheumatology (Oxford) 51:577\u2013578. https:\/\/doi.org\/10.1093\/rheumatology\/ker336","journal-title":"Rheumatology (Oxford)"},{"key":"4800_CR23","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s10165-009-0243-4","volume":"20","author":"A Ogata","year":"2010","unstructured":"Ogata A, Mori M, Hashimoto S, Yano Y, Fujikawa T, Kawa M (2010) Minimal influence of tocilizumab on IFN-gamma synthesis by tuberculosis antigens. Mod Rheumatol 20:130\u2013133. https:\/\/doi.org\/10.1007\/s10165-009-0243-4","journal-title":"Mod Rheumatol"},{"key":"4800_CR24","doi-asserted-by":"publisher","first-page":"bcr2017222826","DOI":"10.1136\/bcr-2017-222826","volume":"2017","author":"S Manabe","year":"2017","unstructured":"Manabe S, Yanagi H, Ozawa H, Takagi A (2017) Necrotising soft tissue infection without systemic toxicity in a patient with rheumatoid arthritis treated with tocilizumab. BMJ Case Rep 2017:bcr2017222826. https:\/\/doi.org\/10.1136\/bcr-2017-222826","journal-title":"BMJ Case Rep"},{"key":"4800_CR25","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/BOR.0000000000000072","volume":"26","author":"D Wallis","year":"2014","unstructured":"Wallis D (2014) Infection risk and biologics. CurrOpinRheumatol 26:404\u2013409. https:\/\/doi.org\/10.1097\/BOR.0000000000000072","journal-title":"CurrOpinRheumatol"},{"key":"4800_CR26","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/ncprheum0338","volume":"2","author":"N Nishimoto","year":"2006","unstructured":"Nishimoto N, Kishimoto T (2006) Interleukin 6: from bench to bedside. Nat ClinPractRheumatol 2:619\u2013626. https:\/\/doi.org\/10.1038\/ncprheum0338","journal-title":"Nat ClinPractRheumatol"},{"issue":"Suppl 2","key":"4800_CR27","doi-asserted-by":"publisher","first-page":"ii2","DOI":"10.1136\/annrheumdis-2013-203348","volume":"72","author":"DE Furst","year":"2013","unstructured":"Furst DE, Keystone EC, So AK, Braun J, Breedveld FC, Burmester GR et al (2013) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 72(Suppl 2):ii2\u2013ii34. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203348","journal-title":"Ann Rheum Dis"},{"key":"4800_CR28","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1136\/annrheumdis-2020-217092","volume":"79","author":"O Lortholary","year":"2020","unstructured":"Lortholary O, Fernandez-Ruiz M, Baddley JW, Manuel O, Mariette X, Winthrop K et al (2020) Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020. Ann Rheum Dis 79:1532\u20131543. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217092","journal-title":"Ann Rheum Dis"},{"key":"4800_CR29","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1136\/ard.2011.151043","volume":"70","author":"A Strangfeld","year":"2011","unstructured":"Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A et al (2011) Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 70:1914\u20131920. https:\/\/doi.org\/10.1136\/ard.2011.151043","journal-title":"Ann Rheum Dis"},{"key":"4800_CR30","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1002\/art.10529","volume":"46","author":"MF Doran","year":"2002","unstructured":"Doran MF, Crowson CS, Pond GR, O\u2019Fallon WM, Gabriel SE (2002) Predictors of infection in rheumatoid arthritis. Arthritis Rheum 46:2294\u20132300. https:\/\/doi.org\/10.1002\/art.10529","journal-title":"Arthritis Rheum"},{"key":"4800_CR31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"JB Galloway","year":"2011","unstructured":"Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP et al (2011) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emph. Rheumatology 50:124\u2013131. https:\/\/doi.org\/10.1093\/rheumatology\/keq242","journal-title":"Rheumatology"},{"key":"4800_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0973-3698(11)60040-X","volume":"6","author":"A Malaviya","year":"2011","unstructured":"Malaviya A, Haroon N (2011) Infections associated with the use of biologic response modifiers in rheumatic diseases: a critical appraisal. Indian J Rheumatol 6:99\u2013112. https:\/\/doi.org\/10.1016\/S0973-3698(11)60040-X","journal-title":"Indian J Rheumatol"},{"key":"4800_CR33","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/annrheumdis-2018-214326","volume":"78","author":"KL Gr\u00f8n","year":"2019","unstructured":"Gr\u00f8n KL, Arkema EV, Glintborg B, Mehnert F, \u00d8stergard M, Dreyer L et al (2019) Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden. Ann Rheum Dis 78:320\u2013327. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214326","journal-title":"Ann Rheum Dis"},{"key":"4800_CR34","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/acr2.11064","volume":"1","author":"G Ozen","year":"2019","unstructured":"Ozen G, Pedro S, England BR, Mehta B, Wolfe F, Michaud K et al (2019) Risk of serious infection in patients with rheumatoid arthritis treated with biologic versus nonbiologic disease-modifying antirheumatic drugs. ACR Open Rheumatol 1:424\u2013432. https:\/\/doi.org\/10.1002\/acr2.11064","journal-title":"ACR Open Rheumatol"},{"key":"4800_CR35","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3390\/biom10071002","volume":"10","author":"J Angelini","year":"2020","unstructured":"Angelini J, Talotta R, Roncato R, Fornasier G, Barbiero G, Dal Cin L et al (2020) JAK-Inhibitors for the treatment of rheumatoid arthritis: a focus on the present and an outlook on the future. Biomolecules 10:1002. https:\/\/doi.org\/10.3390\/biom10071002","journal-title":"Biomolecules"},{"key":"4800_CR36","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s40266-020-00775-w","volume":"37","author":"S Rajasimhan","year":"2020","unstructured":"Rajasimhan S, Pamuk O, Katz JD (2020) Safety of Janus kinase inhibitors in older patients: a focus on the thromboembolic risk. Drugs Aging 37:551\u2013558. https:\/\/doi.org\/10.1007\/s40266-020-00775-w","journal-title":"Drugs Aging"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04800-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-021-04800-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04800-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T06:37:03Z","timestamp":1744180623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-021-04800-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,12]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["4800"],"URL":"https:\/\/doi.org\/10.1007\/s00296-021-04800-y","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"type":"print","value":"0172-8172"},{"type":"electronic","value":"1437-160X"}],"subject":[],"published":{"date-parts":[[2021,2,12]]},"assertion":[{"value":"18 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Ines Doko Vajdi\u0107, Goran \u0160timac, Ivan Pezelj, Matej Mustapi\u0107 and Simeon Grazio declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}